Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Kayla R TunehagDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA.ORCID 0000-0003-3442-7347
Cameron D ThomasDepartment of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida Gainesville FL USA.
Francesco FranchiDivision of Cardiology, Department of Medicine College of Medicine-Jacksonville, University of Florida Jacksonville FL USA.
Joseph S RossiDivision of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA.
Ellen C KeeleyDivision of Cardiovascular Medicine College of Medicine, University of Florida Gainesville FL USA.ORCID 0000-0003-2915-4751
R David AndersonDivision of Cardiovascular Medicine College of Medicine, University of Florida Gainesville FL USA.ORCID 0000-0003-3490-3286
Amber L BeitelsheesUniversity of Maryland School of Medicine Department of Medicine and Program for Personalized and Genomic Medicine Baltimore MD USA.ORCID 0000-0003-0958-7197
Julio D DuarteDepartment of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida Gainesville FL USA.ORCID 0000-0001-9766-4038
Yan GongDepartment of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida Gainesville FL USA.ORCID 0000-0002-8218-1620
Richard A KerenskyDivision of Cardiovascular Medicine College of Medicine, University of Florida Gainesville FL USA.
Caitrin W McDonoughDepartment of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida Gainesville FL USA.ORCID 0000-0001-6393-7288
Anh B NguyenDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA.
Luis Ortega-PazDivision of Cardiology, Department of Medicine College of Medicine-Jacksonville, University of Florida Jacksonville FL USA.ORCID 0000-0002-9567-3253
Sanjay VenkateshDivision of Cardiology, Duke Department of Medicine Duke University School of Medicine Durham NC USA.
Yehua WangDepartment of Pharmaceutical Outcomes & Policy, Department of Epidemiology, and Center for Drug Evaluation and Safety University of Florida Gainesville FL USA.ORCID 0000-0001-7040-1561
Julie A JohnsonDepartment of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida Gainesville FL USA.
Almut G WintersteinDepartment of Pharmaceutical Outcomes & Policy, Department of Epidemiology, and Center for Drug Evaluation and Safety University of Florida Gainesville FL USA.ORCID 0000-0002-6518-5961
George A StoufferDivision of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA.
Dominick J AngiolilloDivision of Cardiology, Department of Medicine College of Medicine-Jacksonville, University of Florida Jacksonville FL USA.ORCID 0000-0001-8451-2131
Larisa H CavallariDepartment of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida Gainesville FL USA.ORCID 0000-0002-7184-5292
Craig R LeeDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA.ORCID 0000-0003-3595-5301
Funding
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5M
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Sparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0M
Precision antiplatelet therapy after percutaneous coronary interventionR01HL149752 · NHLBI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, LEE, CRAIG R · 2020 to 2024
backgroundCytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary intervention (PCI). However, outcome studies to date have lacked racial diversity. Thus, the impact of METHODS AND
resultsAdults among 5 institutions who self-identified as Black or African American, underwent PCI and clinical
conclusionsBlack patients with CYP2C19 intermediate and poor metabolizer phenotypes who are treated with clopidogrel exhibit increased risk of adverse cardiovascular outcomes after PCI in a real-world clinical setting. Bleeding outcomes should be interpreted cautiously. Prospective studies are needed to determine whether genotype-guided use of prasugrel or ticagrelor in intermediate and poor metabolizers improves outcomes in Black patients undergoing PCI.
Indexed as
Black or African AmericanClopidogrelCytochrome P-450 CYP2C19HemorrhagePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsAcute Coronary SyndromeAgedCoronary Artery DiseaseFemaleGenotypeHumansMaleMiddle AgedPharmacogenomic VariantsRetrospective StudiesClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsBlack or African AmericanclopidogrelCYP2C19genetic testingpercutaneous coronary interventionprecision medicine
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.